Hepatocellular Carcinoma Clinical Trial
Official title:
Phase II Trial of Palliative Radiotherapy for Locally Advanced Hepatocellular Carcinoma and Hepatic Metastases
Palliative radiotherapy is radiation treatment given to help reduce pain or discomfort, or
other symptoms related to cancer. This is used commonly for cancer that has spread to the
bones and brain, and for many other primary cancers that are too advanced to be cured,
including lung cancer, pancreatic cancer and head and neck cancer. The benefits of palliative
radiotherapy for advanced liver cancer have not been well studied.
This study is designed to help to see whether palliative radiation therapy is effective in
controlling pain, discomfort or other symptoms related to liver cancer, and how this therapy
Phase II Trial of Palliative Radiotherapy for Locally Advanced Hepatocellular Carcinoma and
Hepatic Metastases might affect the quality of life of patients receiving such therapy. This
information will help the doctors understand if there are specific conditions under which
radiation therapy is more effective and worthwhile, and how it may affect the quality of life
for patients who have locally advanced hepatocellular carcinoma and hepatic metastasis.
The liver is one of the most common sites with tumour involvement, including both primary and
metastatic disease. Gastrointestinal tumours, breast, lung and melanoma are the most common
primary sites for hepatic metastases. Hepatocellular carcinoma(HCC) is the sixth most common
cancer worldwide, with over 600,000 new cases diagnosed per year. It is the third most common
cause of cancer related death.Although, predominately a disease in Asia and sub-Saharan
Africa, the incidence of HCC is increasing in North America. The use of radiation in
unresectable hepatocellular carcinomas, as well as hepatic metastases, for palliation is
uncommon in clinical practice.
This may be because there is a prevailing perception that radiation to the liver will
inevitably lead to radiation induced liver disease (RILD). However, several single
institution, predominantly retrospective studies, have demonstrated effective palliation for
locally advanced HCC as well as hepatic metastases with minimal toxicity.In this study,
palliative radiotherapy (RT), delivered in one fraction of 8Gy, will be given to symptomatic
patients who are not candidates for radical treatment. We hypothesize that palliative RT will
provide symptomatic relief to a large fraction of the patients, with both primary and
metastatic disease. We also expect minimal toxicities at this treatment dose.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |